20:28 , Feb 3, 2017 |  BC Week In Review  |  Company News

Azaya, Cytori deal

Cytori said it will acquire Azaya’s liposomal nanoparticle technology platform, including two cancer drugs: ATI-0918, a generic nanoparticle liposomal formulation of doxorubicin; and ATI-1123 , a liposomal encapsulated docetaxel , which has completed Phase I...
07:00 , Mar 28, 2016 |  BioCentury  |  Strategy

Canbridge can-can

Canbridge Life Sciences Ltd .'s deal with Aveo Pharmaceuticals Inc. will see the Chinese biotech developing its first programs outside Asia. But Chairman and CEO James Xue says the company is not deviating from its...
08:00 , Dec 8, 2014 |  BioCentury  |  Finance

Fast funding for Chinese healthcare innovators

TF Capital plans to invest its inaugural China-focused VC fund in innovation and technology in that nation's healthcare space. The firm, which has about $50 million to invest, has already made about eight investments, including...
02:50 , Dec 3, 2014 |  BC Extra  |  Financial News

Canbridge raises $10M in series A

Canbridge Life Sciences Ltd. (Beijing, China) raised $10 million in a series A round from Qiming Venture Partners and TF Capital. Canbridge in-licenses compounds from small biotechs in the U.S. and Europe to develop in...
08:00 , Feb 17, 2014 |  BioCentury  |  Emerging Company Profile

Canbridge: A bridge to China

Many small biotechs in the U.S. and Europe do not have the resources to develop their programs in China in parallel with Western territories, leading to a five- to eight-year lag before a Chinese launch....
07:00 , Sep 16, 2013 |  BC Week In Review  |  Company News

Azaya, Canbridge deal

Azaya granted Canbridge exclusive rights to develop and commercialize ATI-1123 in China, Taiwan and South Korea. Canbridge is responsible for development and commercialization in the territories. Azaya will be eligible for milestones and royalties. The...
07:00 , Jul 2, 2012 |  BC Week In Review  |  Clinical News

ATI-1123: Phase I data

An open-label, dose-escalation, U.S. Phase I trial in 29 patients with solid tumors showed that 15-110 mg/m 2 IV ATI-1123 given every 3 weeks produced 22 cases of stable disease and 1 partial response consisting...
08:00 , Feb 1, 2010 |  BC Week In Review  |  Clinical News

ATI-1123: Phase I started

Azaya began an open-label, dose-escalation, U.S. Phase I trial to evaluate intravenous ATI-1123 starting at 15 mg/m 2 in about 24 patients. Azaya Therapeutics Inc. , San Antonio, Texas   Product: ATI-1123   Business: Cancer...
07:00 , Oct 5, 2009 |  BC Week In Review  |  Financial News

Azaya completes venture financing

Azaya Therapeutics Inc. , San Antonio, Texas   Business: Drug delivery, Cancer   Date completed: 9/29/09   Type: Venture financing   Raised: $1 million   Investors: Texas Emerging Technology Fund  ...
07:00 , Sep 10, 2007 |  BioCentury  |  Tools & Techniques

Metabasis' quantum hop

The pharmaceutical industry rarely uses free energy perturbation-based methods in computer-aided drug design because these methods have low throughput, require a high level of user expertise and do not always produce results of the desired...